SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported product revenues for the fiscal first quarter ended October 31, 2010 of $23,100, down from product revenues of $221,900 in the same quarter of the prior fiscal year. The quarter’s results include $355,000 in deferred revenue, recorded on the balance sheet as at October 31, 2010, which relates to a single international product shipment. The Company reported a net loss of $2,021,000 or $(0.06) per share for the fiscal first quarter, compared with a net loss of $1,711,200 or $(0.05) per share in the first fiscal quarter last year.
